Today: 20 March 2026
Subscribe
Browse Category

LSE:CPG.L 28 November 2025 - 4 March 2026

Compass Group share price ticks higher today — what’s moving CPG stock in London

Compass Group share price ticks higher today — what’s moving CPG stock in London

Compass Group shares rose 0.6% to 2,197 pence by 0845 GMT Wednesday, after closing up 1.35% Tuesday and rebounding from a 2.62% drop Monday. The stock remains about 23% below its 52-week high, with trading volumes above average. Investors remain focused on AI risks and office demand, with about 20% of revenue tied to corporate clients. Compass will pay its dividend Feb. 26 and switch share trading to U.S. dollars April 1.
25 February 2026
·
Compass Group share price stalls near 2026 low as AI worries keep CPG in focus

Compass Group share price stalls near 2026 low as AI worries keep CPG in focus

Compass Group shares slipped 0.14% to 2,078 pence in light Tuesday trading, after hitting a 2026 low last week. The company reaffirmed 2026 profit guidance and reported 7.3% organic revenue growth, but investor focus remains on AI risks and office catering demand. Compass will switch its London share trading currency to U.S. dollars on April 1. Half-year results are due May 11.
10 February 2026
··
Compass Group PLC stock price slips to 2,125p as AI worries hang over office catering demand

Compass Group PLC stock price slips to 2,125p as AI worries hang over office catering demand

Compass Group shares fell 2.48% to 2,125p on Friday, underperforming the FTSE 100’s 0.59% gain. The caterer reported 7.3% first-quarter organic revenue growth and reiterated its 2026 outlook. Shares hit a three-year low amid investor concerns over AI’s impact on office catering. Compass will switch its London trading currency to U.S. dollars from April 1.
7 February 2026
··
Compass Group share price slips again as AI fears linger after Q1 update

Compass Group share price slips again as AI fears linger after Q1 update

Compass Group shares fell 1.4% to 2,149 pence in early London trading Friday, extending Thursday’s 8% drop. The company confirmed 7.3% organic revenue growth for the quarter and will switch its LSE trading currency to U.S. dollars from April 1. Investors remain concerned about AI’s impact on office catering demand. Compass maintained its 2026 profit outlook.
6 February 2026
··
Compass Group stock nudges up as dividend date nears — here’s what could move CPG next

Compass Group stock nudges up as dividend date nears — here’s what could move CPG next

Compass Group shares rose 0.7% to 2,362 pence in early London trading Monday, ahead of the Jan. 15 ex-dividend date and a Feb. 5 AGM and trading update. The stock remains about 17% below its 52-week high. Broader markets were volatile as Fed Chair Jerome Powell said the Trump administration threatened him with indictment, sending the dollar lower and gold above $4,600 an ounce.
12 January 2026
··
Compass Group PLC Stock (CPG.L) News, Forecasts and Analysis on 15 December 2025: Vermaat Deal Cleared as Analysts Target a Rebound

Compass Group PLC Stock (CPG.L) News, Forecasts and Analysis on 15 December 2025: Vermaat Deal Cleared as Analysts Target a Rebound

Compass Group shares hovered near 2,322p on Monday, close to the lower end of their 52-week range after the EU cleared its €1.5bn Vermaat acquisition. The stock is down 12.6% over 12 months. FY25 results showed $46.1bn revenue, $3,335m operating profit, and 8.7% organic growth. Several brokers say the pullback has improved the stock’s entry point.
15 December 2025
··

Stock Market Today

  • Kessler Topaz Meltzer & Check Files Securities Fraud Class Action Against Soleno Therapeutics
    March 20, 2026, 1:23 PM EDT. Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO) concerning purchases of SLNO stock between March 26 and November 4, 2025. The lawsuit alleges that Soleno made materially false statements and omissions about safety concerns in its Phase 3 clinical trial for diazoxide choline extended-release tablets used to treat hyperphagia linked to Prader-Willi syndrome. The firm claims the company concealed issues relating to excess fluid retention in trial participants. Investors have until May 5, 2026, to seek lead plaintiff status. The complaint is pending in the U.S. District Court for the Northern District of California under case number 3:26-cv-01979. Investors who suffered losses are urged to contact the law firm for legal options at no cost.
Go toTop